Published by AimwellBio. Held by the cohort. Open to the field.
Every other intelligence tool publishes claims. AimwellBio publishes the Standard. The Founding Cohort holds it. The first 100 Signal and Shield subscribers receive it. The field cites it.
In 2026, biopharma decisions are increasingly informed by AI-generated intelligence, regulatory briefs, competitive landscapes, clinical signal summaries. The category has no operating standard. There is no common reference for what source-traced means, what counts as an adversarial verdict, how confidence scores should be constructed, when human review is non-negotiable.
The Adversarial Validation Standard, v1 is AimwellBio’s answer to that gap. It is not a marketing white paper. It is the operating reference the cohort holds the company to, published, versioned, and open to the field as the basis for every signal in the network.
How every output the network produces carries its source chain, from public registry to confidence-scored verdict.
Regulatory, Competitive, Trial Failure, Capital Risk, the four adversarial agents, what each interrogates, how they vote.
PROCEED / DELAY / KILL, the consensus logic, how dissent is preserved, when minority opinion overrides majority.
The math behind the score. How sources are weighted. How temporal decay affects confidence. When a score is too low to publish.
Where AI-generated content enters the chain. Where human review is non-negotiable. The containment boundary.
When the system gets it wrong, documented, with case examples, with corrections. The Standard does not pretend perfection.
How FHIN contributors are credentialed, how their signals are weighted, how the cohort polices itself.
The Founding Cohort Charter integrated. The terms AimwellBio operates under. The cohort’s right to revoke.
The Standard is a published document. Access is tiered, the Cohort and earliest subscribers hold it; the field reads the public abridged edition. Citation is open to anyone; the methodology reference is reserved for those whose work depends on it.
Cortellis, IQVIA, Citeline publish data products. AlphaSense publishes a search interface. None of them publish a Standard, because none of them are positioned to be held to one. AimwellBio is. The Cohort makes that claim enforceable. The Standard makes it citable. v1 is the first edition. v2 will be revised in public, with the Cohort’s input, with the field watching.
This is how a new category becomes the operating norm: someone publishes the reference, the reference gets cited, the citations become the field. AimwellBio is publishing first.
When you cite the methodology behind a decision, how defensible is the citation under cross-examination?
Plus: every Signal/Shield/Command subscriber gets the next published edition of The Standard, on release, before the field at large.
Hand us anything your team is about to use. We return a source-risk review with every citation traced. No sales call. No follow-up sequence. The review itself is the conversation.
The methodology that protects your work is also the methodology that protects your reputation when someone asks where the claim came from.
Cite The Standard In Your Next Brief →Teams searched documents, reviewed guidance updates, followed trial movement, tracked competitors, and built internal briefs by hand. Slow but auditable. Every claim had a paper trail.
Speed. The same brief that took a week now takes minutes. The trade-off: unsupported claims, stale guidance, missing context, and incomplete summaries can now move into serious decisions before anyone challenges them.
AimwellBio is the verification layer that sits between AI-generated intelligence and the decision someone signs their name to. Source-trace, adversarial review, confidence labels, institutional memory.
Seven ways unsupported scientific intelligence can enter regulatory, clinical, board, and investor workflows. Open to credentialed professionals. No sales sequence, no list-trading.
In plain English
A brief is reviewed by four independent agents — regulatory, market, scientific and competitive — which examine it in parallel rather than in sequence. Each reaches its own position. The verdict is the reconciliation of those four positions, not the output of any one of them.
Every claim is traced back to a source. A claim that cannot be resolved to a source does not pass. The output is PROCEED, DELAY or KILL, issued with a confidence score, and it is designed to be attached to the decision a person is accountable for.
Purpose
To make the audit of AI-generated scientific intelligence a documented, repeatable procedure rather than an act of judgement performed privately and differently each time.
Scope
Briefs, memos and claims entering regulatory, clinical, board and investor workflows. The Standard governs how they are audited, not what conclusion they should reach.
Source traceability
Every assertion resolves to the evidence behind it. Citation-resolution gating means an unresolvable claim is contained rather than passed downstream.
Four-agent architecture
Regulatory, market, scientific and competitive reviews run independently and in parallel. Independence is structural: no agent defers to another’s finding.
Evidence hierarchy
Sources are weighted rather than treated as equivalent. Regulatory filings and peer-reviewed literature are not interchangeable with market commentary.
Confidence scoring
Every output carries a confidence score. The score reflects the strength and convergence of the underlying evidence, not the fluency of the language describing it.
Verdict construction
PROCEED, DELAY or KILL. The verdict is a reconciliation across four independent positions; disagreement between them is preserved rather than smoothed away.
Hallucination containment
A fabricated claim must survive four separate adversarial audits and citation-resolution gating. Containment is the mechanism; confidence scoring is the disclosure.
Failure modes
The method is weakest where the evidence base is thin, contested or absent. In those cases the correct output is DELAY or a declared inability to resolve — not a low-confidence PROCEED.
Human review
The Standard is a procedure for producing a defensible record, not a substitute for the accountable person. A verdict informs a decision; it does not make one.
Versioning
Published as v1.0 in September 2026. Revisions are versioned and dated so that a verdict can be read against the edition of the Standard under which it was issued.
Governance
Published by AimwellBio, held by the founding cohort, open to the field for citation. Publishing the method is what makes it auditable by people who did not write it.
Known limitations
The Standard governs process, not outcome. It cannot compensate for an absent evidence base, and it does not claim predictive accuracy. It documents what was checked and what was found.
Who this is for
Regulatory, clinical, medical-affairs and competitive-intelligence teams; investors and capital allocators reviewing scientific claims; and credentialed practitioners who need to know how a verdict was reached before they rely on it.
Use cases
Citing the method in a submission or board paper. Auditing a third party’s AI-generated brief. Establishing internally what “validated” is required to mean before a claim moves forward.
Capabilities and limits
The Standard specifies how a claim is audited, how sources are weighted, and how confidence is disclosed. It does not specify what conclusion to reach, and it makes no claim of predictive accuracy.
Availability
Published as a PDF with a reference HTML edition, open to the field for citation. Held by the founding cohort; the first 100 Signal and Shield subscribers receive each edition on release.
AimwellBio, explained
Frequently asked questions about the methodology, answered in plain language. The full treatment is in the Standard itself.
Adversarial validation is the practice of assigning independent reviewers to challenge a claim rather than confirm it. Instead of one model producing an answer, separate agents examine the same brief from opposing angles and must converge before a verdict is issued. Disagreement is treated as signal, not noise — it is the mechanism that surfaces weak evidence.
Each brief is routed through four independent audits — regulatory, market, scientific, and competitive — which run in parallel rather than in sequence. Their findings are reconciled into one consensus verdict with a confidence score, and every output is source-traced back to the evidence it rests on. The full methodology is published as the Adversarial Validation Standard.
Four independent agents audit every brief along distinct axes: regulatory, market, scientific, and competitive. Each reaches its own position without deferring to the others, and the verdict is the reconciliation of those four positions rather than the output of any single one. Consensus across independent reviewers is what makes a PROCEED defensible.
Every Cortex output carries a verdict confidence score, is source-traced, and is hallucination-contained through citation-resolution gating — a claim that cannot be resolved to a source does not pass. Independent adversarial review adds a second layer: a fabricated claim must survive four separate audits rather than one generous reader.
AimwellBio draws on regulatory filings, clinical and scientific literature, market and competitive signals, and the contributor network behind FHIN. Outputs are traced to their sources rather than asserted, and the evidence hierarchy and confidence scoring that govern how sources are weighted are documented in the published Standard.
Observer access is free for credentialed professionals. Methodology published as the Adversarial Validation Standard, v1.0 (2026-09). Security and compliance posture: /security.